𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Palifermin-induced acral erythrodysaesthesia variant in the treatment of acute myeloid leukaemia

✍ Scribed by Olivia Milne; Briony Cutts; Catriona McLean; Douglas Gin


Book ID
108929013
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
351 KB
Volume
52
Category
Article
ISSN
0004-8380

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Clofarabine in the treatment of poor ris
✍ Janusz Krawczyk; Naeem Ansar; Ronan Swords; Tracy Murphy; Barry MacDonagh; Teres πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 92 KB

## Abstract Clofarabine is a second generation nucleoside analogue. It inhibits DNA repair and activates the mitochondrial apoptotic pathway leading to cell death. __In vitro__ clofarabine has demonstrated synergy with daunorubicin and Ara‐C and in phase II clinical trials has shown promising activ

New synergistic combinations of differen
✍ H. T. Hassan; L. E. Zyada; M. H. Ragab; J. K. H. Rees πŸ“‚ Article πŸ“… 1991 πŸ› Springer 🌐 English βš– 681 KB

Differentiation inducing agents in double and triple combinations can induce differentiation in primary culture of more than 80% of blast cells from some AML patients. In the present study, the interactions between these differentiating agents have been analysed using Berenbaum's general algebraic s

Oral idarubicin in the treatment of acut
✍ S. T. A. Malik; J. Tucker; A. Z. S. Rohatiner; W. Brace; T. A. Lister πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 307 KB

Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/ day). No complete remissions or return to chronic phase CML were observed. A fall in the per